AGIOS PHARMACEUTICALS INC's ticker is AGIO and the CUSIP is 00847X104. A total of 216 filers reported holding AGIOS PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 0.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,677,851 | -9.5% | 1,198,960 | +3.6% | 0.00% | 0.0% |
| Q2 2023 | $32,785,138 | +31.0% | 1,157,667 | +6.3% | 0.00% | +33.3% |
| Q1 2023 | $25,022,584 | +84321.7% | 1,089,359 | +3.2% | 0.00% | -25.0% |
| Q4 2022 | $29,640 | -99.9% | 1,055,558 | +2.8% | 0.00% | 0.0% |
| Q3 2022 | $29,043,000 | +16.5% | 1,026,982 | -8.6% | 0.00% | 0.0% |
| Q2 2022 | $24,919,000 | -15.9% | 1,124,004 | +10.4% | 0.00% | 0.0% |
| Q1 2022 | $29,624,000 | -13.7% | 1,017,680 | -2.5% | 0.00% | 0.0% |
| Q4 2021 | $34,316,000 | -29.0% | 1,044,016 | -0.4% | 0.00% | -42.9% |
| Q3 2021 | $48,353,000 | -16.3% | 1,047,742 | -0.1% | 0.01% | -12.5% |
| Q2 2021 | $57,802,000 | +48.4% | 1,048,850 | +39.0% | 0.01% | +33.3% |
| Q1 2021 | $38,956,000 | +24.0% | 754,382 | +4.0% | 0.01% | +20.0% |
| Q4 2020 | $31,424,000 | +27.0% | 725,231 | +2.6% | 0.01% | 0.0% |
| Q3 2020 | $24,745,000 | -37.1% | 707,027 | -3.9% | 0.01% | -37.5% |
| Q2 2020 | $39,342,000 | +52.9% | 735,653 | +1.4% | 0.01% | +14.3% |
| Q1 2020 | $25,729,000 | -60.5% | 725,185 | -46.9% | 0.01% | 0.0% |
| Q4 2019 | $65,214,000 | +242.9% | 1,365,742 | +132.6% | 0.01% | +75.0% |
| Q3 2019 | $19,020,000 | -34.3% | 587,048 | +1.2% | 0.00% | -42.9% |
| Q2 2019 | $28,928,000 | -20.1% | 579,957 | +8.0% | 0.01% | -22.2% |
| Q1 2019 | $36,217,000 | -28.1% | 537,035 | -50.9% | 0.01% | +12.5% |
| Q4 2018 | $50,404,000 | +37.0% | 1,093,136 | +129.2% | 0.01% | -20.0% |
| Q3 2018 | $36,783,000 | -7.5% | 476,965 | +1.0% | 0.01% | -16.7% |
| Q2 2018 | $39,786,000 | +14.8% | 472,359 | +11.5% | 0.01% | +9.1% |
| Q1 2018 | $34,642,000 | +64.0% | 423,601 | +14.6% | 0.01% | +57.1% |
| Q4 2017 | $21,125,000 | -13.4% | 369,512 | +1.1% | 0.01% | -22.2% |
| Q3 2017 | $24,393,000 | +36.9% | 365,439 | +5.5% | 0.01% | +28.6% |
| Q2 2017 | $17,821,000 | +15.6% | 346,389 | +31.3% | 0.01% | +16.7% |
| Q1 2017 | $15,410,000 | +51.6% | 263,899 | +8.3% | 0.01% | +20.0% |
| Q4 2016 | $10,163,000 | -12.3% | 243,563 | +11.0% | 0.01% | -16.7% |
| Q3 2016 | $11,593,000 | +49.8% | 219,502 | +18.8% | 0.01% | +50.0% |
| Q2 2016 | $7,740,000 | +7.8% | 184,770 | +4.5% | 0.00% | 0.0% |
| Q1 2016 | $7,180,000 | -35.9% | 176,869 | +2.5% | 0.00% | -33.3% |
| Q4 2015 | $11,201,000 | -3.0% | 172,544 | +5.4% | 0.01% | -14.3% |
| Q3 2015 | $11,550,000 | +31.7% | 163,634 | +107.4% | 0.01% | +40.0% |
| Q2 2015 | $8,770,000 | +18.5% | 78,910 | +0.5% | 0.01% | +25.0% |
| Q1 2015 | $7,401,000 | -6.3% | 78,501 | +11.3% | 0.00% | -20.0% |
| Q4 2014 | $7,899,000 | +109.7% | 70,502 | +14.8% | 0.01% | +150.0% |
| Q3 2014 | $3,766,000 | +38.5% | 61,400 | +3.5% | 0.00% | 0.0% |
| Q2 2014 | $2,719,000 | +79.4% | 59,343 | +53.2% | 0.00% | +100.0% |
| Q1 2014 | $1,516,000 | +65.0% | 38,729 | +0.9% | 0.00% | 0.0% |
| Q4 2013 | $919,000 | -13.1% | 38,386 | +1.5% | 0.00% | 0.0% |
| Q3 2013 | $1,058,000 | – | 37,828 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Rock Springs Capital Management LP | 3,057,869 | $86,477,000 | 2.23% |
| Eagle Health Investments LP | 329,713 | $9,324,000 | 2.14% |
| Bellevue Group AG | 4,058,792 | $114,783,000 | 1.65% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 959,214 | $27,127,000 | 1.13% |
| ARMISTICE CAPITAL, LLC | 1,924,000 | $54,411,000 | 0.94% |
| Integral Health Asset Management, LLC | 100,000 | $2,828,000 | 0.55% |
| Monarch Partners Asset Management LLC | 57,820 | $1,635,000 | 0.49% |
| ArrowMark Colorado Holdings LLC | 1,380,389 | $39,037,000 | 0.48% |
| AlphaCentric Advisors LLC | 15,000 | $424,000 | 0.44% |
| PDT Partners, LLC | 72,778 | $2,058,000 | 0.31% |